Cite

    Laszlo, G., Alonzo, T., Gudgeon, C., Harrington, K., Kentsis, A., Gerbing, R., Wang, Y., Ries, R., Raimondi, S., Hirsch, B., Gamis, A., Meshinchi, S., & Walter, R. (2016). erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Journal of hematology & oncology, 9(1), 1. http://access.bl.uk/ark:/81055/vdc_100080937761.0x0000c3